Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab plus standard therapy in pediatric systemic lupus erythematosus
2011-000368-88Phase 2Unknown
- Sponsor
- GSK
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Benlysta plus standard therapy with Placebo plus standard therapy (2 arms). Primary endpoint: Primary efficacy endpoint. Status: unknown.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2011-000368-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000368-88.